Much of the controversy regarding ivermectin involves "Evidence" that the drug has a benefit in treatment of COVID. Detractors will often use the hyperbolic claim that there is no evidence that ivermectin is useful in this setting.
A large randomized, double-blind placebo-controlled trial would go a long way to resolving the controversies regarding ivermectin in the treatment of COVID-19.
One of the discoverers of ivermectin, Satoshi Omura, who was awarded a Nobel Prize for his accomplishment, reportedly approached Merck about conducting a large, rigorous trial of ivermectin in the treatment of COVID in Japan.
Governments are spending billions on COVID-related interventions, yet they show no interest in even a preliminary study of ivermectin.
A cynical view is that Merck is interested in promoting its novel agent molnupiravir, a drug that it would sell to the United States government for $700 dollars per course of treatment, as compared to less than $3 a course for ivermectin.
Another consideration is that conducting a valid, large trial of ivermectin in the treatment of COVID will be expensive and complex.
At least, provide data that would tend to support or refute the hypothesis that ivermectin has a role in treating COVID. The response to the COVID pandemic has produced a number of distressing and questionable policies: mandates, lockdowns, threatening people's jobs, and contributing to the psychological effects of uncertainty and increasing authoritarianism.
https://www.americanthinker.com/articles/2021/10/ivermectin_the_elephant_in_the_room.html
No comments:
Post a Comment